Main > A1. CORP. INDEX. N-Nm > Nexus Pharmaceuticals Inc./P C2



Nexus Pharmaceuticals Inc./P C2's subsections
2017. 06.01. Na Nitroprusside Inj.
2017. 08.03. Isoproterenol.HCl Inj.
2020. 04.21. USA>FDA-approved
2020. 06.26. USA>Launch
2023. 03.01. USA FDA Approval
2023. 07.24. USA FDA Approval
2023. 09.26. USA FDA Approval
web-site

Nexus Pharmaceuticals Inc./P C2's products
This section has no products